AN EVALUATION OF DRUG COST CONTROL POLICY AT NAKHON PATHOM HOSPITAL
Keywords:
evaluation, policy, drug cost controlAbstract
Drug spending expenditure of Nakhon Pathom Hospital has been found to continuously increase through the past few years. The drug cost control policy has been implemented since the fiscal year of 2021 by the Pharmacy and Therapeutic Committee, which is divided into two main aspects namely, the price control policy and the policy of the rational use of drugs. This descriptive study aimed to assess the effectiveness and the impact of drug cost control policies on drug expenditure, which focused on the non-essential drugs, and antimicrobial drugs that are on the drug list of Nakhon Pathom Hospital. The research article is a descriptive analysis comparing drug expenditure before and after the policy implementation for 1 year. The collective data was accumulated in the fiscal year of 2020 and the fiscal year of 2021 comparatively, before and after the implementation of the drug cost control policy, respectively. The results of the study after full official implementation of the drug cost control policies showed that the drug expenditure in the fiscal year of 2021 appeared to be reduced to 39,023,292.93 baht, which was lower than the expected approval budget (8.29% reduction). Compared to the budget in the fiscal year of 2020, the reduction of the drug expenditure in the fiscal year of 2021 is 5,258,046.93 baht (1.20% reduction). The expenditure for non-essential drugs appeared to have been reduced to 13,472,900.87 baht (10.73% reduction). The use of antimicrobial drugs (DDD/100bed-day) in the group of the beta-lactam plus beta-lactamase inhibitors (BL/BI), and tigecycline was decreased, except carbapenems and colistin which had an increased cost of usage during the time of the study. This study showed that the appropriate use of restricted antimicrobial drugs was 100%. By comparison, drug expenditure on 16 groups of non-essential drugs in the fiscal year of 2021 decreased significantly from the previous year. The conclusion of the study of the drug cost control policies was to help the reduction of hospital expenditure and lead to enhance the effectiveness of financial management budgeting of Nakhon Pathom Hospital.
References
International Health Policy Program Foundation. Thai National health accounts 2017-2019 [Internet]. 2021 [Cited on 2022 Aug 15]. Available from: http://ihppthaigov.net/DB/publication/attachresearch/457/chapter1.pdf. (in Thai)
Tunpaiboon N. Business/Industry Trends 2021-2023: Pharmaceutical industry [Internet]. [Cited on 2022 Aug 15]. Available from: https://www.krungsri.com/th/research/ industry/industry-outlook/Chemicals/phamaceuticals/IO/ io-pharmaceuticals-21. (in Thai)
The Comptroller General's Department. The integration project to Develop a health insurance system. Clarification document for Draft Budget Expenditure Act for the fiscal year 2019. The National Legislative Assembly. (in Thai)
Suanrueang P, Topark-ngarm A, Sakolchai S, Limwattananon C, Suriyawongpaisal P, Srithamrongsawat S. Measures for promoting rational use of high cost drugs in hospitals under Civil Servant Medical Benefit Scheme. J Health syst Res. 2013;7(2):223-34. (in Thai)
Health insurance system research office. Report the results of the development of data collection system monitor drug orders and provide feedback to the hospital July 2011-March 2012. (in Thai)
Yingseree B. Outpatient drug cost containment in civil servant medical benefit scheme: lessons from Lampang hospital. J Health Sci. 2012;21(5):972-85. (in Thai)
Upakdee N, Pansang S. Responsiveness to glucosamine negative list policy of civil servant medical benefit scheme. J Health Syst Res. 2014;8(3):230-37. (in Thai)
Hathaidumrongwittaya M, Upakdee N. Assessment of the impact of policies to control the cost of drug and medical supplies at Tharuea Hospital, Phra nakorn sri ayuttaya province. HCU J Health Sci. 2017;20(40)77-86. (in Thai)
Mininstry of Public Health (Thailand). Health Administration Division. Service plan: rational drug use [Internet]. Nonthaburi: The Division; 2016 [cited 2017 Oct 21]. Available from: https://mrd-hss.moph.go.th/mrd1_hss/ wpcontent/uploads/2019/04/service-plan-RDU.pdf (in Thai)
Nakhonpathom Hospital. Annual Report of Nakhonpathom Hospital, fiscal year 2020. Nakhonpathom; 2020 (in Thai)
Theppitak T. Applying concept of gap analysis to customer satisfaction for Thai port in Bangkok. SJMS. 2007;25(1):25–39. (in Thai)
HO Collaborating Center for Drug Statistics Methodology. (2017). Guidelines for ATClassification and DDD assignment 2018. Norway: Norwegian Institute of Public Health.
Government Procurement and Inventory Management Act B.E. 2560 (2017). Royal Thai Government Gazette 134, chapter 210 special edition (2017 August 23) (in Thai)
Department of Medical services, Ministry of Public Health. EE-AMR Tool, Thailand. Bangkok: 2022 (in Thai)
Office of the Permanent Secretary Ministry of Public Health. Drug procurement action plan 2021. Nakhonpathom Hospital; 2022 (in Thai)
Antimicrobial resistance control committee of Nakhonpathom Hospital. Rational Drug Use hospital manual. N.P.: Projects of Nakhonpathom hospital to support and promote the rational use of antimicrobial drugs; 2020 (in Thai)
Drug and Medical Supply Information Center, Ministry of Public Health. Pharmaceutical management information report [Internet]. 2020 [Cited on 2022 Nov 12]. Available from: http://203.157.3.54/hssd1/???b3B0aW9uPXJlcG9yd CZtb2R1bGU9cmVwb3J0JnVtZD1hcHAxJkZpc1llYXI9MjU2MyZxPSZtb2Q9cmVwb3J0X21haW40JlpvbmVJRD0mWm9uZVNlcnZJRD0mUHJvdmluY2VJRD0mYXJlYV90eXBlPTQmZ3JvdXBfPSZzZXRfPTMmQ2hrWm9uZT0mUHJvdmluY2VJRF92aWV3PSZWaWV3PVkm (in Thai)
Pacey S, Warner J, Li wan Po A. A multidisciplinary approach to hospital-based drug cost containment. J Clin Pharm Ther. 1998;23: 203-11.
Covid-19 situation, develop RDU-AMR to meet the target. Minutes of the meeting of the health service system development committee for rational drug use (RDU) in Health Region 5; 2022 Apr 12; Krathumbaen Hospital, Thailand (in Thai)
Downloads
Published
Issue
Section
License
All articles published and information contained in this journal such as text, graphics, logos and images is copyrighted by and proprietary to the Thai Bulletin of Pharmaceutical Sciences, and may not be reproduced in whole or in part by persons, organizations, or corporations other than the Thai Bulletin of Pharmaceutical Sciences and the authors without prior written permission.
